Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) have been assigned a consensus recommendation of “Moderate Buy” from the eight ratings firms that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $48.38.

TARS has been the subject of a number of research analyst reports. Oppenheimer reaffirmed an “outperform” rating and issued a $59.00 target price (up from $55.00) on shares of Tarsus Pharmaceuticals in a research note on Wednesday, February 28th. Barclays upped their price objective on Tarsus Pharmaceuticals from $40.00 to $50.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 28th. The Goldman Sachs Group increased their price objective on Tarsus Pharmaceuticals from $19.00 to $30.00 and gave the stock a “neutral” rating in a report on Thursday, February 29th. Jefferies Financial Group boosted their target price on Tarsus Pharmaceuticals from $30.00 to $44.00 and gave the company a “buy” rating in a research note on Wednesday, March 6th. Finally, HC Wainwright raised their price target on shares of Tarsus Pharmaceuticals from $50.00 to $57.00 and gave the stock a “buy” rating in a research note on Wednesday, February 28th.

Tarsus Pharmaceuticals Stock Down 2.8 %

Shares of Tarsus Pharmaceuticals stock opened at $32.76 on Thursday. The company has a market capitalization of $1.12 billion, a P/E ratio of -7.06 and a beta of 1.05. The company has a debt-to-equity ratio of 0.15, a current ratio of 6.93 and a quick ratio of 6.85. The business has a 50-day moving average of $33.98 and a two-hundred day moving average of $24.69. Tarsus Pharmaceuticals has a 1 year low of $12.57 and a 1 year high of $40.40.

Tarsus Pharmaceuticals (NASDAQ:TARS) last released its quarterly earnings results on Tuesday, February 27th. The company reported ($1.31) earnings per share for the quarter, beating the consensus estimate of ($1.37) by $0.06. The company had revenue of $13.08 million during the quarter, compared to analyst estimates of $4.63 million. During the same quarter last year, the company earned ($0.49) EPS. As a group, equities analysts predict that Tarsus Pharmaceuticals will post -4.25 EPS for the current year.

Insider Buying and Selling

In other Tarsus Pharmaceuticals news, COO Seshadri Neervannan sold 4,879 shares of the firm’s stock in a transaction that occurred on Monday, March 18th. The stock was sold at an average price of $30.60, for a total value of $149,297.40. Following the completion of the transaction, the chief operating officer now directly owns 64,767 shares in the company, valued at $1,981,870.20. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Tarsus Pharmaceuticals news, COO Seshadri Neervannan sold 4,879 shares of the company’s stock in a transaction on Monday, March 18th. The shares were sold at an average price of $30.60, for a total transaction of $149,297.40. Following the sale, the chief operating officer now directly owns 64,767 shares of the company’s stock, valued at $1,981,870.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, General Counsel Bryan Wahl sold 4,436 shares of Tarsus Pharmaceuticals stock in a transaction dated Monday, March 18th. The shares were sold at an average price of $30.60, for a total transaction of $135,741.60. Following the completion of the transaction, the general counsel now directly owns 40,951 shares of the company’s stock, valued at approximately $1,253,100.60. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 24,496 shares of company stock worth $749,578. Corporate insiders own 11.54% of the company’s stock.

Institutional Investors Weigh In On Tarsus Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Simplicity Wealth LLC acquired a new position in Tarsus Pharmaceuticals in the first quarter valued at about $223,000. Nations Financial Group Inc. IA ADV bought a new position in shares of Tarsus Pharmaceuticals in the 1st quarter valued at $218,000. Raymond James Financial Services Advisors Inc. raised its holdings in shares of Tarsus Pharmaceuticals by 16.3% during the 1st quarter. Raymond James Financial Services Advisors Inc. now owns 50,950 shares of the company’s stock worth $1,852,000 after buying an additional 7,131 shares in the last quarter. Allspring Global Investments Holdings LLC lifted its position in shares of Tarsus Pharmaceuticals by 2.6% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 192,303 shares of the company’s stock worth $6,990,000 after buying an additional 4,889 shares during the last quarter. Finally, TFG Asset Management GP Ltd lifted its position in shares of Tarsus Pharmaceuticals by 30.1% during the 4th quarter. TFG Asset Management GP Ltd now owns 800,000 shares of the company’s stock worth $16,200,000 after buying an additional 185,000 shares during the last quarter. Institutional investors and hedge funds own 90.01% of the company’s stock.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.